AbbVie Forms Auto-Immunology Partnership with HotSpot Therapeutics for US$335M
By Swati Sharan
Pharma Deals Review: Vol 2022 Issue 12 (Table of Contents)
Published: 21 Dec-2022
DOI: 10.3833/pdr.v2022.i12.2756 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AbbVie has entered into a global collaboration and license agreement with HotSpot Therapeutics, in a deal worth up to US$335 M, to develop a small molecule interferon regulatory factor 5 (IRF5) inhibitor for the treatment of autoimmune diseases, leveraging the latter’s proprietary Smart Allostery™ drug discovery platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS